ProCE Banner Activity

DOLCE: DTG/3TC in Treatment-Naive People Living With HIV and Low CD4+ Cell Counts

Conference Coverage
Slideset

In people living with HIV and CD4+ cell counts ≤200 cells/mm3, virologic response rates—regardless of baseline HIV-1 RNA—were comparable in participants receiving DTG/3TC vs DTG + XTC/TDF. 

Released: November 15, 2024

Expiration: November 14, 2025

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from Gilead Sciences, Inc. and ViiV Healthcare.

Gilead Sciences, Inc.

ViiV Healthcare